Professional Documents
Culture Documents
Patologi Atanatomi Colon Anus Rectum
Patologi Atanatomi Colon Anus Rectum
CHROHN’s DESEASE
EPIDEMIOLOGI
•It can affect any part of the gastrointestinal tract from the
mouth to the anus. For typical sites & proportion of patients
affected see below:
Epidemiology
Other: anorectal,
gastroduodenual, oral only
– 5%
Epidemiology
Genetic Environmental
susceptibility factors
Host
Immune
Response
Crohn’s Disease
The mutations appear to alter monocyte recognition of the constituent flora of the
gut. It is possible that functional defects in CARD15 prevent innate immunity from
balancing resistance to the microbes in the gut in CD patients, leading to
uncontrolled inflammation and mucosal damage.
However the CARD15 mutations only account for 20-30% of cases of CD and CD is
not found in oriental populations who have the mutations. Therefore this gene is
not necessary for CD.
It is likely that there are other susceptibility genes that influence how the immune
system interacts with the gut flora which may be discovered in the future. Putative
loci have been mapped to chromosome 12 (IBD2), 6 (IBD3) and 14 (IBD4).
Environmental Factors
A wide range of environmental factors have been
Environmental
factors found to play a role:
Smoking – Patients with CD are more likely to have been smokers and smoking
may worsen CD and increase the risk of relapse/surgical intervention.
Drugs – the oral contraceptive pill has been linked epidemiologically with CD.
Relapse may be precipitated by NSAIDs.
Immune response
Host Both the potential genetics underlying CD and the
Immune
Response
environmental and host factors surrounding the patient
may be considered as initiating factors for CD, but the
exact aetiology is unknown.
In CD, a dominant CD4 Th1 reaction is induced. The mechanisms for this are
displayed diagrammatically on the next page.
The immune system and CD
Luminal antigen’s (from
CD mucosal bacteria/food)
macrophages Gut epithelium – limits but doesn’t
produce large exclude antigens from entering the
amounts of lamina propria. In CD there is an
cytokines increased permeability.
IL-12 & IL-18 M
Th1
CD4
which induce Interferon- - recruits
the Th1
leukocytes to the site
recruitment CD4
resulting in increased
of Th1 cells Th1
inflammation.
CD4
Th1 also have abnormal apoptosis TNF- -causes
sustained by these cytokines. increased inflammation.
Very rare.
Undernutrition
•Caused by reduced food intake, malabsorption,
increased protein loss from inflamed bowel and
the increased metabolic demands of being sick.
Short bowel syndrome
•Develops when extensive bowel resection
leads to excessive malabsorption of fluids,
electrolytes and nutrients.
Cancer
•With Crohn’s colitis, there is a increased risk of
colorectal carcinoma
•There is an small increased risk of rarer small
intestinal and anal cancers occurring in cites of
prolonged inflammation.
Extra-intestinal complications
There are many systemic associations and complications of CD, most affecting the
liver and biliary tree, joints, skin and eyes:
Barium follow-through
Colonoscopy, terminal ileoscopy – findings consistent
& biopsy: These allow direct with Crohn’s include
visualisation and allows for a an asymmetrical
biopsy of the mucosa to be alteration in mucosal
taken. This is central to pattern with deep
macroscopic and microscopic ulceration and areas of
diagnosis. narrowing or
stricturing.
Ultrasound & CT
scanning: Can help
define thickness of the
bowel and mesentery
and can be useful to
evaluate disease
progress & chart
fistula formation.
Diagnosis
Blood tests
Biochemistry: C-reactive protein and serum albumin suggests active CD. Liver
biochemistry may be abnormal.
Stool cultures
•If diarrhoea is bloody (as it sometimes is with colonic CD), other causes could
be ulcerative colitis, infective colitis, colorectal cancer, ischaemia or iatrogenic
causes (NSAIDs or antibiotics)
•Causes of abdominal pain, diarrhoea and weight loss include ulcerative colitis,
infective colitis and other forms of colitis, cancer (of pancreas, colorectal, small
bowel lymphomas or endocrine tumours), ischaemia coeliac disease and
irritable bowel disease.
Medical management
•Dietary advice and nutritional support including vitamin supplementation to
counter-act any deficiencies that develop.
•The BNF information about the drugs on this page can be seen HERE
Surgical management
•Surgery is indicated for perforation or haemorrhage (emergency) or for small-bowel
obstruction, Crohn's colitis, abscess (intra-abdo and perianal), fistulas and
inflammation unresponsive to medical therapy.
Morbidity
The pattern of CD is a lifelong duration with periods of active disease alternating
with periods of remission. The disease causes significant disability with only 75% of
patients being fully capable of work in the first year of disease and 15% of patients
unable to work after 5-10years of the disease.
People with CD are also more at risk of developing certain cancers and other
complications as mentioned under the clinical features section of this module.
Epidemiology
Increases with age
Age 40 <5%
Age 60 30%
Age 85 65%
Epidemiology
Gender prevalence depends on age
Submucosa
Serosa
Pathophysiology
Segmentation = motility process in which the segmental
muscular contractions separate the lumen into chambers
Associated symptoms
Nausea/vomiting 20-62%
Constipation 50%
Diarrhea 25-35%
Urinary symptoms (dysuria, urgency, frequency)
10-15%
Diagnosis of Diverticulitis
Right sided diverticulitis tends to cause RLQ abdominal
pain; can be difficult to distinguish from appendicitis
Diagnosis of Diverticulitis
Physical examination
Low grade fever
LLQ abdominal tenderness
Usually moderate with no peritoneal signs
Painful pseudo-mass in 20% of cases
Rebound tenderness suggests free perforation and peritonitis
Antibiotics
Uncomplicated diverticulitis
Antibiotics
Coverage of fecal flora
Gram negative rods, anaerobes
Common regimens
Cipro + Flagyl x 10 days
Augmentin or Unsayn x 10 days
Uncomplicated diverticulitis
Monitoring clinical course
Pain should gradually improve several days
(decrescendo)
Normalization of temperature
Tolerance of po intake
Purpose
Exclude neoplasm
Evaluate extent of the diverticulosis
Prognosis after resolution
30-40% of patients will remain asymptomatic
Colovesical fistula:
pneumaturia, dysuria, fecaluria
Sigmoid resection
Colostomy
Rectal stump
3 months later colostomy takedown and colorectal
anastomosis
Common Anorectal desease
Benign Anal Rectal Disease
Waldeyer’s Fascia
Supralevator Space
Superficial Postanal
Space
ANAL CANAL
Peritoneum
Supralevator
Levator Ani m. Space
Puborectalis m.
Ischioanal Space
Deep External
Sphincter m.
Intersphincteric
Space
Internal
Sphincter m.
Perianal Space
Transverse Septum
ANAL CANAL
Column of
Anal Morgagni
Transitional
Zone Dentate Line
Anal Crypt
Anal Gland
Anoderm
Patient complaints
Anal Pain
Bleeding
Drainage
Time course
Right Left
Tailbone
Abscess Classification
Ischioanal - 40-60%
Supralevator 2% or less Rare
Supralevator
Abscess
Intersphincteric
Abscess
Ischioanal Abscess
Perianal Abscess
HORSESHOE ABSCESS
Supralevator
Space
Intersphincteric
Space
Ischioanal Space
Anorectal Abscess
Treatment of Perianal and
Ischiorectal Abscesses
Diagnosis - usually straightforward
Erythema and Pain over affected area
Fluctuance
Treatment
Incision and Drainage
+/- Excision of small amount of overlying skin
Initial packing for hemostasis
Drainage catheter (Pezzer) or pack wound
Attention to good hygiene and control blood sugar
Antibiotics if immunocompromised, obese or
diabetic
Small Radial incision
Short distance from anus – feel for soft spot
Place drain and trim – avoids packing
Follow up in 7-10 days to remove drain
Peri anal abscess - ? Antibiotics
Not usually indicated if there is adequate drainage
Indicated for patients with:
Obesity
Diabetes
Imunocompromised
Extensive large abscess or recurrent abscess
Fistula-in-Ano
Definition
abnormal connection between two epithelial
surfaces.
Classification:
Parks: Defines fistula by course of tract
Goodsall’s rule
Diagnosis
Treatment
Goals
Options
Fistula-in-Ano
Goodsall’s Rule
Posterior
Anterior
Fistula in ano
Fistula in ano: Surgical disease
Refer to Colon and Rectal Surgeon or General
Surgeon
Reassure patient – rarely cancer, most do not
need a colostomy
If suspect Crohns
Gain control of perianal sepsis
Then complete full workup and staging
Goals of therapy
Get rid of the fistula/connection
Preserve continence
Fissure in Ano
Pathogenesis
Acute fissure results from trauma to the anal
canal most commonly from a large fecal bolus
Secondary changes of chronic fissure include
Sentinel pile or skin tag at the distal end
Hypertrophied anal papilla-swelling, edema and
fibrosis near the dentate line
Fibrosis of the internal sphincter at the base
Fissure with Sentinel Tag
Fissure with Sentinel Tag
Fissure in Ano
Symptoms
Pain is the main symptom
Sharp, cutting or tearing during defecation
Duration is few minutes to hours
Bleeding – bright red and scant
Skin Tag
Mucous discharge resulting in itching
Fissure in Ano
Diagnosis
Diagnosis often made on history alone
Inspection – gently spread the buttocks and the
fissure becomes apparent
Triad of chronic anal fissure
Sentinel pile
Hypertrophied anal papilla
Anal ulcer
Fissure in Ano
Differential Diagnosis
Intersphincteric abscess
Pruritus Ani
Fissure from inflammatory bowel disease
Carcinoma of the anus
Infectious Perianal conditions
Leukemic infiltration
Acute Fissure in Ano
Treatment
Increase dietary fiber
Local anesthetic to prevent spasm
Nitroglycerin or Nifedepine Ointment
Not commercially available
Must be mixed by pharmacist
Warm tub soaks
4-6 weeks of treatment
Chronic Fissure in Ano
Surgical Treatment